A Phase 2 interventional study of SYN111 and Placebo in Generalized Anxiety Disorder, sponsored by Biotie Therapies Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-02-27.
Sponsored by Biotie Therapies Inc. (part of Acorda Therapeutics) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.
Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 70th largest by enrollment of the 234 interventional ones that give a count, is one of 20 that started in 2008, is one of 21 in phase 2, and was the 48th registered.
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
Browse Generalized Anxiety Disorder studies →38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:
Virginia Polytechnic Institute and State University · Sites in United States
Ages 18–65
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18+
Intra-Cellular Therapies, Inc. · Sites in United States
Ages 18+
BTL Industries Ltd. · Sites in United States
Ages 22+
Intra-Cellular Therapies, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
265 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 32 · Phase 3 51 · Phase 4 28
First in 1991; this study’s year is marked. 20 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 239 is above the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.
Median enrollment 90 across the 234 interventional studies, 220 across the 28 observational. Of the 199 that completed or were terminated, 90 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 265 have an industry lead sponsor. The 10 most frequent:
This study is registered under Biotie Therapies Inc., one of the names counted as Acorda Therapeutics. Under that name alone:
Biotie Therapies Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Acorda Therapeutics has 1 study filed under Generalized Anxiety Disorder — fewer than ten, so there is no comparison to draw.
20 of the studies in Generalized Anxiety Disorder with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07123467Phase 3Wayne State UniversityCannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder | 2027-08-31 |
| NCT06846320AbbVieStudy to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | 2026-11 |
| NCT06723158Boston UniversityOral Surgery Virtual Reality Glasses Study | 2026-12 |
| NCT04557891University of California, Los AngelesLow-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD) | 2026-12 |
| NCT05467683Jasper A. SmitsCO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy | 2026-12-01 |
Add all 20 to your calendar (.ics) → With an account.
Among the 265 studies in Generalized Anxiety Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder.
This was an exploratory study to evaluate the effect of 500 or 1000 mg per day for 8 weeks of Rufinamide compared to placebo on measures of anxiety in patients with Generalized Anxiety Disorder, and to determine tolerability of Rufinamide in this population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
500 mg 1 week, followed by 1000 mg for 7 weeks
Drug: SYN111
0 mg tablets
Drug: Placebo
500 mg for 1 week followed by 1000 mg for 7 weeks
Also known as: Rufinamide
0 mg tablets
Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed
The Hamilton Anxiety Scale is a 14-item test measuring the severity of anxiety symptoms. It provides measures of overall anxiety, psychic anxiety (mental agitation and psychological distress), and somatic anxiety (physical complaints related to anxiety). The interviewer then rated the individuals on a 5-point scale for each of the 14 items. Seven of the items specifically address psychic anxiety and the remaining 7 items address somatic anxiety. The total anxiety score ranges from 0 to 56. The 7 psychic anxiety items elicit a psychic anxiety score that ranges from 0 to 28. The remaining 7 items yield a somatic anxiety score that also ranges from 0 to 28. A score of 17 or less indicates mild anxiety severity. A score from 18 to 24 indicates mild to moderate anxiety severity, a score of 25 to 30 indicates a moderate to severe anxiety and lastly a score of 31-56 is very severe. HAM-A total score is the sum of items 1 - 14.
Time frame: 8 Weeks
Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics
The Hospital Anxiety and Depression Scale is a self screening questionnaire for depression and anxiety. It consists of 14 questions, seven for anxiety and seven for depression. The 14 statements are relevant to either generalized anxiety (7 statements) or 'depression' (again 7). Each question has 4 possible responses. Responses are scored on a scale from 3 to 0. The maximum score is therefore 21 for depression and 21 for anxiety. A score of 11 or higher indicates the probable presence of the mood disorder with a score of 8 to 10 being just suggestive of the presence of the respective state. The 2 subscales, anxiety and depression, have been found to be independent measures. In its current form the HADS is now divided into 4 ranges: normal (0-7), mild (8-10), moderate (11-15) and severe (16-21). Anxiety score = sum of items 1, 3, 5, 7, 9, 11, and 13. Depression score = sum of items 2, 4, 6, 8, 10, 12, and 14.
Time frame: 8 Weeks
Change From Baseline in Montgomery-Asberg Depression Scale (MADRS) Summary Statistics.
The MADRS (Montgomery and Asberg 1979) is a clinician-rated instrument that measures the presence and severity of depression. This instrument consists of 10 items. Each item is rated on a defined step scale of 0 to 6 with anchors at 2-point intervals. The MADRS total score is the sum of the 10 items and ranges from 0 to 60. A high numeric rating shows a greater degree of symptom severity.
Time frame: 8 Weeks
Change From Baseline in Clinical Global Impression Scale for Severity of Illness: (CGI-S)
Severity of illness is the first scale in the CGI. A rating is filled in by the investigator at the start of treatment based on a 0-7 point weighted scale. It goes from not assessed (0), to among the most extremely ill patients (7).
Time frame: 8 weeks
Change From Baseline Raskin Depression Scale.
It explores the extent to which an individual demonstrates depression on three sub-scales (rated 1-5): verbal self-report, behavior and secondary symptoms of depression. Scores range from 3-15, with higher scores indicating greater severity.
Time frame: 8 weeks
Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed
The Covi Anxiety Scale is a simple 3 item scale for the assessment of severity of anxiety symptoms. The scale measures 3 dimensions: verbal report, behavior and somatic symptoms of anxiety. Each item scored on a scale of 1 - 5. (1)not at all, (2)somewhat, (3)moderately, (4) considerably, and (5)very much), hence the scale is a 5- to 15 point range. The three items are the patient's verbal report (feeling shaky, jittery, jumpy), observed behavior consistent with anxiety during the interview (e.g. appearing frightened, shaky, restless) and somatic complains (e.g., sweating, trembling, heart pounding). COVI Rating Scale total score is the sum of items 1 - 3.
Time frame: 8 weeks
A total of 239 subjects were randomized into the trial from 19 of the 20 study sites initiated.
| Milestone | Rufinamide | Placebo |
|---|---|---|
| Started | 120 | 119 |
| Completed | 115 | 114 |
| Not completed | 5 | 5 |
The Hamilton Anxiety Scale is a 14-item test measuring the severity of anxiety symptoms. It provides measures of overall anxiety, psychic anxiety (mental agitation and psychological distress), and somatic anxiety (physical complaints related to anxiety). The interviewer then rated the individuals on a 5-point scale for each of the 14 items. Seven of the items specifically address psychic anxiety and the remaining 7 items address somatic anxiety. The total anxiety score ranges from 0 to 56. The 7 psychic anxiety items elicit a psychic anxiety score that ranges from 0 to 28. The remaining 7 items yield a somatic anxiety score that also ranges from 0 to 28. A score of 17 or less indicates mild anxiety severity. A score from 18 to 24 indicates mild to moderate anxiety severity, a score of 25 to 30 indicates a moderate to severe anxiety and lastly a score of 31-56 is very severe. HAM-A total score is the sum of items 1 - 14.
| score on a scale | Rufinamide | Placebo |
|---|---|---|
| Screening | 25.5 ± 3.70 | 25.6 ± 3.77 |
| Baseline | 25.5 ± 3.77 | 25.8 ± 3.74 |
| Week 1 | 21.9 ± 6.04 | 21.4 ± 5.71 |
| Week 2 | 20.0 ± 6.29 | 19.6 ± 5.97 |
| Week 3 | 18.0 ± 7.45 | 17.8 ± 7.02 |
| Week 6 | 15.7 ± 7.34 | 16.7 ± 7.32 |
| Week 8 | 15.1 ± 7.76 | 15.1 ± 7.19 |
| Last Observation | 16.7 ± 7.91 | 16.1 ± 7.65 |
The Hospital Anxiety and Depression Scale is a self screening questionnaire for depression and anxiety. It consists of 14 questions, seven for anxiety and seven for depression. The 14 statements are relevant to either generalized anxiety (7 statements) or 'depression' (again 7). Each question has 4 possible responses. Responses are scored on a scale from 3 to 0. The maximum score is therefore 21 for depression and 21 for anxiety. A score of 11 or higher indicates the probable presence of the mood disorder with a score of 8 to 10 being just suggestive of the presence of the respective state. The 2 subscales, anxiety and depression, have been found to be independent measures. In its current form the HADS is now divided into 4 ranges: normal (0-7), mild (8-10), moderate (11-15) and severe (16-21). Anxiety score = sum of items 1, 3, 5, 7, 9, 11, and 13. Depression score = sum of items 2, 4, 6, 8, 10, 12, and 14.
| score on a scale | Rufinamide | Placebo |
|---|---|---|
| Week 1 | -0.2 ± 2.66 | -0.1 ± 2.02 |
| Week 2 | -0.4 ± 2.42 | -0.4 ± 2.69 |
| Week 3 | -1.0 ± 3.14 | -0.5 ± 2.91 |
| Week 6 | -1.4 ± 3.57 | -1.2 ± 3.20 |
| Week 8 | -2.0 ± 3.61 | -1.6 ± 3.07 |
| Last Observation | -1.2 ± 3.74 | -1.4 ± 3.01 |
The MADRS (Montgomery and Asberg 1979) is a clinician-rated instrument that measures the presence and severity of depression. This instrument consists of 10 items. Each item is rated on a defined step scale of 0 to 6 with anchors at 2-point intervals. The MADRS total score is the sum of the 10 items and ranges from 0 to 60. A high numeric rating shows a greater degree of symptom severity.
| score on a scale | Rufinamide | Placebo |
|---|---|---|
| Change From Baseline in Montgomery-Asberg Depression Scale (MADRS) Summary Statistics. | 15.7 ± 5.51 | 16.4 ± 4.86 |
Severity of illness is the first scale in the CGI. A rating is filled in by the investigator at the start of treatment based on a 0-7 point weighted scale. It goes from not assessed (0), to among the most extremely ill patients (7).
| score on a scale | Rufinamide | Placebo |
|---|---|---|
| Change From Baseline in Clinical Global Impression Scale for Severity of Illness: (CGI-S) | 4.5 ± 0.60 | 4.4 ± 0.56 |
It explores the extent to which an individual demonstrates depression on three sub-scales (rated 1-5): verbal self-report, behavior and secondary symptoms of depression. Scores range from 3-15, with higher scores indicating greater severity.
| score on a scale | Rufinamide | Placebo |
|---|---|---|
| Change From Baseline Raskin Depression Scale. | 5.2 ± 1.22 | 5.3 ± 1.20 |
The Covi Anxiety Scale is a simple 3 item scale for the assessment of severity of anxiety symptoms. The scale measures 3 dimensions: verbal report, behavior and somatic symptoms of anxiety. Each item scored on a scale of 1 - 5. (1)not at all, (2)somewhat, (3)moderately, (4) considerably, and (5)very much), hence the scale is a 5- to 15 point range. The three items are the patient's verbal report (feeling shaky, jittery, jumpy), observed behavior consistent with anxiety during the interview (e.g. appearing frightened, shaky, restless) and somatic complains (e.g., sweating, trembling, heart pounding). COVI Rating Scale total score is the sum of items 1 - 3.
| score on a scale | Rufinamide | Placebo |
|---|---|---|
| Screening | 10.7 ± 1.39 | 10.5 ± 1.26 |
| Baseline | 10.7 ± 1.35 | 10.6 ± 1.33 |
| Week 3 | 8.3 ± 2.51 | 8.1 ± 1.99 |
| Week 6 | 7.5 ± 2.51 | 7.6 ± 2.21 |
| Week 8 | 7.1 ± 2.50 | 7.4 ± 2.17 |
| Last Observation | 7.7 ± 2.73 | 7.7 ± 2.29 |
Collected over 8 Weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rufinamide | 0/115 (0%) | 1/115 (0.9%) | 75/115 (65.2%) |
| Placebo | 0/114 (0%) | 1/114 (0.9%) | 72/114 (63.2%) |
| Event | Rufinamide | Placebo |
|---|---|---|
| Ecotopic PregnancyPregnancy, puerperium and perinatal conditions | 0/115 | 1/114 |
| Acute BronchitisInfections and infestations | 1/115 | 0/114 |
| Event | Rufinamide | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 14/115 | 22/114 |
| NauseaGastrointestinal disorders | 10/115 | 12/114 |
| SomnolenceNervous system disorders | 12/115 | 10/114 |
| Upper respiratory tract infectionInfections and infestations | 7/115 | 9/114 |
| ConstipationGastrointestinal disorders | 8/115 | 1/114 |
| DizzinessNervous system disorders | 6/115 | 7/114 |
| Dry MouthGastrointestinal disorders | 6/115 | 5/114 |
| FatigueGeneral disorders | 4/115 | 5/114 |
| RashSkin and subcutaneous tissue disorders | 5/115 | 0/114 |
| DiarrhoeaGastrointestinal disorders | 3/115 | 4/114 |
ITT Population: Randomized and received at least one dose of the study drugs.
| Age, Continuous(years) | Rufinamide | Placebo | Total |
|---|---|---|---|
| Mean | 38.4 ± 12.47 | 35.6 ± 11.53 | 37.0 ± 12.07 |
| Sex: Female, Male(Participants) | Rufinamide | Placebo | Total |
|---|---|---|---|
| Female | 76 | 81 | 157 |
| Male | 39 | 33 | 72 |
| Ethnicity (NIH/OMB)(Participants) | Rufinamide | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 19 | 31 |
| Not Hispanic or Latino | 103 | 95 | 198 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Rufinamide | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 12 | 8 | 20 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 14 | 17 | 31 |
| White | 82 | 69 | 151 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 7 | 18 | 25 |
| Region of Enrollment(participants) | Rufinamide | Placebo | Total |
|---|---|---|---|
| United States | 115 | 114 | 229 |
The record gives a start of Mar 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2019, 10 years 3 months after primary completion. A results delay was requested in Dec 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rufinamide
Generalized Anxiety Disorder →